Research Center for Evidence-Based Medicine, Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
The Joanna Briggs Institute, The University of Adelaide, Adelaide, South Australia, Australia.
Curr Pharm Biotechnol. 2020;21(11):1042-1051. doi: 10.2174/1389201021666200416123931.
Probiotics can be used for the treatment of viral gastroenteritis.
This systematic review is to evaluate the evidence regarding the effect of probiotics on human cases of viral gastroenteritis.
The objective of this review is to evaluate the effectiveness of probiotics against placebo or standard treatment for viral gastroenteritis. A comprehensive search of Cochrane Library, EMBASE, MEDLINE via PubMed and Ovid databases, and unpublished studies (till 27 January 2018) was conducted followed by a process of study selection and critical appraisal by two independent reviewers. Randomized controlled trials assessing probiotic administration in human subjects infected with any species of gastroenteritis viruses were considered for inclusion. Only studies with a confirmed viral cause of infection were included. This study was developed using the JBI methodology for systematic reviews, which is in accordance with the PRISMA guideline. Meta-analysis was conducted where feasible. Data were pooled using the inverse variance method with random effects models and expressed as Mean Differences (MDs) with 95% Confidence Intervals (CIs). Heterogeneity was assessed by Cochran Q statistic and quantified by the I2 statistic. We included 17 RCTs, containing 3,082 patients.
Probiotics can improve symptoms of viral gastroenteritis, including the duration of diarrhea (mean difference 0.7 days, 95% CI 0.31 to 1.09 days, n = 740, ten trials) and duration of hospitalization (mean difference 0.76 days, 95% CI 0.61 to 0.92 days, n = 329, four trials).
The results of this review show that the administration of probiotics in patients with viral gastroenteritis should be considered.
益生菌可用于治疗病毒性胃肠炎。
本系统评价旨在评估益生菌对人类病毒性胃肠炎病例的疗效证据。
本综述的目的是评估益生菌对抗安慰剂或病毒性胃肠炎标准治疗的有效性。通过 Cochrane 图书馆、EMBASE、MEDLINE 通过 PubMed 和 Ovid 数据库以及未发表的研究（截至 2018 年 1 月 27 日）进行全面检索，然后由两名独立评审员进行研究选择和批判性评估过程。评估益生菌在感染任何一种胃肠炎病毒的人类受试者中的给药情况的随机对照试验被认为符合纳入标准。仅包括经证实的感染病毒病因的研究。本研究采用 JBI 系统评价方法学进行开发，符合 PRISMA 指南。在可行的情况下进行了荟萃分析。使用具有随机效应模型的Inverse Variance 方法对数据进行汇总，并以均值差异（MDs）和 95%置信区间（CIs）表示。通过 Cochran Q 统计量评估异质性，并通过 I2 统计量进行量化。我们纳入了 17 项 RCT，包含 3082 名患者。
益生菌可以改善病毒性胃肠炎的症状，包括腹泻持续时间（平均差异 0.7 天，95%CI 0.31 至 1.09 天，n = 740，10 项试验）和住院时间（平均差异 0.76 天，95%CI 0.61 至 0.92 天，n = 329，4 项试验）。
本综述的结果表明，在病毒性胃肠炎患者中使用益生菌应予以考虑。
